Burden of illness in idiopathic pulmonary fibrosis

Journal of Medical Economics

Volumn 15, Issue 5, 2012, Pages 829-835

  Collard, Harold R ^a   Ward, Alex J ^b   Lanes, Stephan ^b   Cortney Hayflinger, D ^c   Rosenberg, Daniel M ^d   Hunsche, Elke ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c Hayflinger Analytic Services   (United States)

^d ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Comorbidity; Costs and cost analysis; Idiopathic pulmonary fibrosis; Resource utilization

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST OF ILLNESS; EMPHYSEMA; FEMALE; FIBROSING ALVEOLITIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; ICD-9; INCIDENCE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; OXYGEN THERAPY; PREVALENCE; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; COST OF ILLNESS; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; UNITED STATES;

EID: 84865231686     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.680553     Document Type: Article

References (15)

1. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-6
2. Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007;176:277-84
3. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64
4. Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011;139:609-16
5. Nicholson AG, Colby TV, du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000;162:2213-7
6. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203
7. Priest JL, Cantrell CR, Fincham J, et al. Quality of care associated with common chronic diseases in a 9-state medicaid population utilizing claims data: An evaluation of medication and health care use and costs. Popul Health Manag 2011;14:43-54
8. Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:832-7
9. Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 2010;104:1035-41
10. Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 2009;103:927-31
11. Harris JM, Johnston ID, Rudd R, et al. Cryptogenic fibrosing alveolitis and lung cancer: The BTS study. Thorax 2010;65:70-6
12. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: Connecting the dots. Am J Respir Crit Care Med 2007;175:875-80
13. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity. Eur Respir J 2005; 26:586-93
14. Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007;30:715-21
15. Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: Decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136:10-5